Biopharma's stock market winners of 2022 revealed
5
(546)
Write Review
More
$ 39.00
In stock
Description
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
Quarterly shareprice performance
Edgar Antonio Arguelles Sainos on LinkedIn: Biopharma's stock
Predicting the Life Sciences Investment Market in 2022
The Other Omicron: The Missing $200 Billion of Pharma Industry
VC funding trends in biotechnology
Fate Therapeutics
Evaluate Search
Pharma 2023 Half-year review reveals winners and losers
The Top 100 Healthcare Technology Companies of 2022
The Inflation Reduction Act's impact on pharma
Stock Market Activity
Evaluate Search
The top 10 biopharma M&A deals of 2022
The top 10 biopharma M&A deals of 2022
